Skip to content
ETopical – Lifestyle
Author:
Johnson & Johnson Innovative Medicine
New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn’s disease patient subgroups
October 15, 2026
TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn’s disease
October 15, 2026
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
September 29, 2026